Your browser doesn't support javascript.
loading
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations.
Doroshow, Deborah B; O'Donnell, Peter H; Hoffman-Censits, Jean H; Gupta, Sumati V; Vaishampayan, Ulka; Heath, Elisabeth I; Garcia, Philip; Zhao, Qianqian; Yu, Menggang; Milowsky, Matthew I; Galsky, Matthew D.
Affiliation
  • Doroshow DB; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • O'Donnell PH; University of Chicago, Chicago, IL.
  • Hoffman-Censits JH; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
  • Gupta SV; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
  • Vaishampayan U; Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
  • Heath EI; Karmanos Cancer Center, Detroit, MI.
  • Garcia P; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Zhao Q; University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Yu M; University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Milowsky MI; University of North Carolina, Chapel Hill, NC.
  • Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
JCO Precis Oncol ; 7: e2300095, 2023 07.
Article in En | MEDLINE | ID: mdl-37410974

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urologic Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Middle aged Language: En Journal: JCO Precis Oncol Year: 2023 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urologic Neoplasms / Poly(ADP-ribose) Polymerase Inhibitors Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Middle aged Language: En Journal: JCO Precis Oncol Year: 2023 Document type: Article Country of publication: United States